Cumberland Pharmaceuticals Partners with RedHill Biopharma to Co-Commercialize Talicia® for H. pylori Treatment

Cumberland Pharmaceuticals and RedHill Biopharma Forge Strategic Partnership for Talicia®

Cumberland Pharmaceuticals Inc. announces a significant strategic partnership with RedHill Biopharma Ltd. to co-commercialize Talicia®, an FDA-approved treatment for Helicobacter pylori (H. pylori) infection, a leading cause of gastric cancer. With a $4 million investment, Cumberland secures a 30% ownership stake in the Talicia business, allowing both companies to benefit from the product’s financial performance while sharing operational responsibilities. This collaboration is designed to enhance Talicia's market presence, capitalizing on its status as the top prescribed therapy for H. pylori among U.S. gastroenterologists.

Talicia stands out in the market due to its unique formulation that combines omeprazole, amoxicillin, and low-dose rifabutin, delivering high eradication rates of the bacteria and establishing itself as a first-line treatment according to the American College of Gastroenterology Clinical Guidelines. The product is also noted for its patent protection until 2042 and eight years of Qualified Infectious Disease Product (QIDP) market exclusivity, which positions it favorably against antibiotic resistance. Through this partnership, Cumberland aims to utilize its national sales force to amplify Talicia's reach, thereby driving prescription growth and reinforcing its leadership within the gastroenterology sector.

CEO A.J. Kazimi highlights the importance of this collaboration, stating it presents a robust growth opportunity for Cumberland as it seeks to enhance patient access to this critical therapy. The establishment of a jointly owned entity will enable both companies to share resources and expertise across sales, marketing, and supply chain management. By leveraging RedHill's established framework, Cumberland not only strengthens its portfolio but also aligns with its mission to deliver high-quality pharmaceutical solutions that improve patient care.

In addition to the strategic implications of this partnership, the transaction is poised to strengthen RedHill's financial position, aligning with its broader strategic goals. This collaboration illustrates the potential for operational synergies, allowing both companies to optimize their resources in an increasingly competitive market. The partnership marks a pivotal moment for Cumberland Pharmaceuticals, as it expands its offerings in the gastroenterology field with a market-leading product that addresses a significant healthcare need.